USPTO serial 79300505
RZNOMICS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 14, 2021
- Examiner
- FOSTER, ALEXANDRA M.
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with RZNOMICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Ophthalmic preparations; pharmaceutical products for the treatment of viral and infectious disease, for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceuticals for the treatment of cancer disease, neurodegenerative disease, neurodevelopmental disorder, eye disease, muscular disease, infectious disease, cardiovascular disease, gastrointestinal disease, blood disease, metabolic disease, immune disease, genetic disease; pharmaceutical preparations acting on the central nervous system for the treatment of dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, neuromuscular disorders, neurodevelopmental disorders, neurovascular disease; anti-cancer preparations; cardiovascular pharmaceuticals; pharmaceutical preparations for immunity adjustment; pharmaceutical preparations for the use in hematology; anti-diabetic pharmaceuticals; pharmaceutical products for the treatment of infectious disease; anti-dermoinfectives; pharmaceutical preparations for the treatment of kidney disease; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations in the nature of autonomic drugs for medical purposes; pharmaceutical products for treating respiratory disease; pharmaceutical preparations for treating epidermal problems; viral vaccines; anti-viral agents, namely, anti-viral disinfectants; pharmaceutical and veterinary preparations for the treatment of cancer disease, neurodegenerative disease, eye disease, muscular disease, infectious disease, cardiovascular disease, gastrointestinal disease, blood disease, metabolic disease, immune disease, genetic disease | ACTIVE | — |
| 042 | Research and development of vaccines and medicines; drug discovery services; scientific research for medical purposes in the field of cancerous disease; scientific research for medical purposes in the area of cancerous disease; research and development in the fields of pharmaceutical and biotechnology; testing, inspection or research of pharmaceuticals, cosmetics or foodstuff; pharmaceutical products development; research on the subject of pharmaceuticals; clinical studies of medicines, namely, clinical research in the field of cancer therapy, neurodegenerative disease therapy, neurodevelopmental disorder therapy, eye disease therapy, muscular disease therapy, infectious disease therapy, cardiovascular disease therapy, gastrointestinal disease therapy, blood disease therapy, metabolic disease therapy, immune disease therapy, genetic disease therapy, radiology, chemotherapy; medical research services for assessing the efficiency of pharmaceuticals; pharmaceutical drug development services; scientific research in the field of pharmacy; consultancy pertaining to pharmacology; medicine research, namely, research and development of vaccines and medicines; testing of pharmaceuticals; research in the field of medical products; providing information on the test, inspection, and research of medical products; consultation and providing information in the fields of pharmacology; industrial research in the fields of medicine, health and pharmacology; analysis of human tissues for medical research | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 21, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 27, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 27, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 14, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 14, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 12, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 28, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 28, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 8, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 24, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 24, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 24, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 24, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 24, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 24, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 23, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 23, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 23, 2021 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 23, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 23, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 23, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 23, 2021 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 23, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 28, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 28, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 28, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 27, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 24, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 2, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 29, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 24, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |